Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $17,989.11 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Pascal Deschatelets sold 909 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $19.79, for a total value of $17,989.11. Following the completion of the transaction, the insider owned 1,157,310 shares of the company’s stock, valued at approximately $22,903,164.90. This represents a 0.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pascal Deschatelets also recently made the following trade(s):

• On Thursday, January 22nd, Pascal Deschatelets sold 5,928 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $21.77, for a total transaction of $129,052.56.
• On Tuesday, January 13th, Pascal Deschatelets sold 2,277 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $22.19, for a total transaction of $50,526.63.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $21.76 on Friday. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $2.75 billion, a P/E ratio of 70.18 and a beta of 0.31. The firm has a 50-day moving average price of $23.02 and a two-hundred day moving average price of $23.52. Apellis Pharmaceuticals, Inc. has a twelve month low of $16.10 and a twelve month high of $30.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Thursday, October 30th. The company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The business had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. During the same period in the prior year, the business earned ($0.46) earnings per share. The company’s quarterly revenue was up 133.0% on a year-over-year basis. As a group, research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Trending Headlines about Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. HC Wainwright cut their price target on Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating for the company in a report on Friday, October 31st. Cantor Fitzgerald cut their target price on shares of Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a research note on Tuesday, January 13th. Stifel Nicolaus reduced their target price on shares of Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Wolfe Research initiated coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 6th. They set a “peer perform” rating for the company. Finally, Robert W. Baird boosted their price objective on shares of Apellis Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Twelve research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $33.53.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently modified their holdings of APLS. Simplify Asset Management Inc. acquired a new stake in Apellis Pharmaceuticals during the 3rd quarter worth approximately $2,419,000. Corton Capital Inc. purchased a new stake in Apellis Pharmaceuticals during the second quarter worth approximately $364,000. Wealth Enhancement Advisory Services LLC increased its position in shares of Apellis Pharmaceuticals by 43.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 100,666 shares of the company’s stock worth $1,838,000 after acquiring an additional 30,507 shares in the last quarter. Highland Capital Management LLC purchased a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $1,135,000. Finally, Schroder Investment Management Group raised its stake in shares of Apellis Pharmaceuticals by 91.9% in the 2nd quarter. Schroder Investment Management Group now owns 485,615 shares of the company’s stock valued at $8,406,000 after acquiring an additional 232,506 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.